Marwan Hariz, MD, PhD and Jordan P. Amadio, MD, MBA
Deep brain stimulation (DBS) for enhancements of non-disease states is ethically indefensible given our incomplete knowledge of this technology. Attention should instead be focused on increasing access to DBS for patients with illnesses potentially treatable by the procedure.
Allan B. Peetz, MD, Nicholas Sadovnikoff, MD, and Michael F. O’Connor, MD
Because of their serious medical conditions and the nature of the treatments, patients who are candidates for extracorporeal life support may not be able to give properly informed consent for the treatment.
AMA J Ethics. 2015;17(3):236-242. doi:
10.1001/journalofethics.2015.17.3.stas1-1503
Although there are valid reasons to suspend do-not-resuscitate (DNR) orders during surgery, the decision to do so should be discussed with patients and should take into account their goals and objectives.
AMA J Ethics. 2015;17(3):229-235. doi:
10.1001/journalofethics.2015.17.3.nlit1-1503
Withholding information from patients during an informed consent process is ethically unacceptable. Patients may restrict the amount of information they wish to receive or designate someone else to receive the information for them.
AMA J Ethics. 2015;17(3):209-214. doi:
10.1001/journalofethics.2015.17.3.ecas2-1503.
When a would-be living organ donor wants to accept risk in the name of altruism when there is little chance for benefit or significant chance for harm, physicians are justified in limiting that altruism.
The guidelines for patients’ eligibility for bariatric surgery have not changed since 1991, although recent data suggest there may be indications for broadening application of the surgery.
A discussion of the ethical issues raised by a patient’s request for off-label, prophylactic bariatric surgery to prevent diabetes mellitus type 2 (DM type 2).
A discussion of the ethical issues raised by a patient’s request for off-label, prophylactic bariatric surgery to prevent diabetes mellitus type 2 (DM type 2).
Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process?